Scientific Advisory Board (SAB)

The NIBN has an International Scientific Advisory Board (SAB) of independent, internationally renowned experts. The SAB is responsible for the definition of the NIBN's goals, including the specialization fields of research at the NIBN, setting the academic and professional goals and standards of the NIBN and for the evaluation of the NIBN programs and members.

• Prof. Sir Aaron Klug OM FRS (member since 2006)

• 
  Recipient of the 1982 Nobel Prize in Chemistry and former President of the British Royal Society, member and former Director of the Medical Research Council Laboratory of Molecular Biology at the University of Cambridge, UK.
  Prof. Klug is an outstanding structural biologist who pioneered the crystallography of biological assemblies and the founder of three-dimensional electron microscopy.
  His own research laid the foundation for the computerized tomography (CT) scanners that have become standard hospital equipment.
  Prof. Klug is a member of the Order of Merit and a Foreign Associate of both the US National Academy of Sciences and of the French Academy of Sciences. He has received many honorary degrees and is an Honorary Fellow of Peterhouse and Trinity Colleges, Cambridge. Prof. Klug is a member of the Scientific Advisory Boards of several companies, including Sangamo, Geneva Proteomics and Cambridge Antibody Technology. Pivotal in the creation of the Sanger Centre in Cambridge, which sequenced one third of the human genome.
  

• Prof. Raymond Dwek FRS (member since 2006)

• 
  Prof. Dwek is the Founder and Director of Oxford's Glycobiology Institute and its spin-off biotechnology company, Oxford GlycoSciences, amongst the most successful such companies in Europe.
  He is a Professor of Glycobiology at the University of Oxford since 1988 and a former head of the Department of Biochemistry at the University of Oxford (2000-2006), UK, a fellow of the British Royal Society and the European Molecular Biology Organization. Prof. Dwek brings with him an uncanny ability to transform discoveries in basic science into commercially viable ventures. 
  Prof Dwek is also a Director of United Therapeutics, one of the fastest growing biotech companies in the USA.  
  Prof. Dwek has been awarded the prestigious award of Commander of the Most Excellent Order of the British Empire (CBE) in the Diplomatic Services and Overseas New Year 2013 Honours list for services to UK-Israel scientific collaboration.
  Prof. Dwek Serves as a Special Advisor on Biotechnology to the President of Ben-Gurion University and played an instrumental role in helping to establish the NIBN. Prof. Dwek is also co-chair of the BIRAX initiative on Regenerative Medicine.
  

• Prof. Philip Needleman (member since 2006)

• 
  Prof. Needleman spent 25 years at Washington University School of Medicine where he was professor and chairman of the department of pharmacology.  As the developer of the breakthrough drug for arthritis, Celebrex, he has devoted his life to the design of new drugs. In addition to being an expert on inflammation, he is recognized worldwide for his research on organic nitrates, his work on blood pressure regulation and the discovery of atrial natriuretic factor. A member of the US National Academy of Sciences and its council, Prof. Needleman brings with him a wealth of experience in both academia and industry, having served as Chair of the Department of Pharmacology at Washington University School of Medicine for more than two decades and Senior Executive Vice-President, Chief Scientific Officer and Chairman of Research and Development of the Pharmacia Corporation. Prof. Needleman currently serves in senior positions and is on numerous Boards of civic organizations.
  

• Prof. Richard Ulevitch (member since 2010)

• 
  Chairman Emeritus of the Department of Immunology at The Scripps Research Institute and Chairman of 5AM Venture's Scientific Advisory Board. Ulevitch has been affiliated with multiple advisory panels including the National Institutes of Health, the American Heart Association, and the Food and Drug Administration. He is currently a scientific advisor to Aravis Ventures (Zurich, Switzerland) and a consultant to biotechnology and pharmaceutical companies. He was a founding scientific advisor to the Lombard Odier Darier Hentsch Immunology Fund (Geneva, Switzerland).
  

• Prof. Hermona Soreq (member since 2013)

• 
  Professor of Molecular Neuroscience at The Hebrew University of Jerusalem (HUJ), recipient of Israeli Ministry of Health prize. Best known for her work on the signaling of acetylcholine and its relevance in stress responses and Parkinson's and Alzheimer's diseases. In 1986,  became an Associate Professor of Molecular Biology in the Department of Biological Chemistry at the HUJ; served as the head of the Silberman Institute of Life Sciences (1995-2000) and Dean of the HUJ Faculty of Science (2005-2008). Her research is focused on the mechanisms underlying malfunctioning of communication by the neurotransmitter acetylcholine in muscle, nerves and blood cells, which involves changes in pre-mRNA processing and microRNA regulators and may be manipulated by Oligonucleotide-mediated therapeutics (successfully completed Phase II clinical trials for treating inflammatory bowel disease).